BMT CTN PROTOCOL 1302, Multicenter Phase II, Double Blind, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Type of Cancer
Multiple Myeloma

Sponsor
NMDP BMT

Protocol Number
NMDP BMT CTN 1302

To Learn More Call
(201)-510-0950